

LISTING OF CLAIMS

The current listing of claims supersedes all previous listings of claims.

1. (Currently Amended) A pharmaceutical composition for topical administration comprising:

(i) a therapeutically safe and effective amount of lidocaine or of a pharmaceutically acceptable salt thereof;

(ii) a therapeutically safe and effective amount of prilocaine or of a pharmaceutically acceptable salt thereof; and

(iii) a therapeutically safe and effective amount of tetracaine or of a pharmaceutically acceptable salt thereof,

wherein the pharmaceutical composition is administered without occlusion.

2. (Previously Presented) The pharmaceutical composition according to claim 1, further comprising water.

3. (Previously Presented) The pharmaceutical composition according to claim 1, wherein lidocaine or its salt on the one side, and prilocaine or its salt on the other side, form an eutectic mixture.

4. (Previously Presented) The pharmaceutical composition according to claim 3, wherein one or more of lidocaine or its salt is in an amount from about 0.5% to about 5% w/w, prilocaine or its salt is in an amount from about 0.5% to about 5% w/w, and tetracaine or its salt is in an amount from about 0.5% to about 8% w/w.

5. (Previously Presented) The pharmaceutical composition according to claim 4, wherein lidocaine or its salt is in an amount of about 1.5% w/w, and prilocaine or its salt is in an amount of about 1.5% w/w.

6. (Canceled)

7. (Previously Presented) The pharmaceutical composition according to claim 4, wherein tetracaine or its salt is in an amount of about 4% w/w.
8. (Previously Presented) The pharmaceutical composition according to claim 1, further comprising appropriate amounts of pharmaceutically acceptable excipients to constitute a topical formulation.
9. (Previously Presented) The pharmaceutical composition according to claim 8, wherein the excipients comprise one or a combination of two or more of at least one skin penetration enhancer, at least one spreading agent, at least one viscosity increasing agent, at least one surfactant, and at least one preservative.
10. (Previously Presented) The pharmaceutical composition according to claim 9, wherein the skin penetration enhancer includes one or both of methylpyrrolidone and dimethyl sulfoxide (DMSO).
11. (Previously Presented) The pharmaceutical composition according to claim 10, wherein methylpyrrolidone is in an amount from about 5% to about 20% w/w.
12. (Previously Presented) The pharmaceutical composition according to claim 11, wherein methylpyrrolidone is in an amount of about 10% w/w.
13. (Canceled)
14. (Previously Presented) The pharmaceutical composition according to claim 10, wherein dimethyl sulfoxide is in an amount from about 0.5% to about 5% w/w.
15. (Previously Presented) The pharmaceutical composition according to claim 14, wherein dimethyl sulfoxide is in an amount of about 2% w/w.

16. (Canceled)

17. (Previously Presented) The pharmaceutical composition according to claim 9, wherein the spreading agent is selected from hyaluronidases and derivatives of mucopolysaccharidases.

18. (Canceled)

19. (Previously Presented) The pharmaceutical composition according to claim 9, wherein the viscosity increasing agent is selected from guar gum and a carbomer.

20. (Previously Presented) The pharmaceutical composition according to claim 9, wherein the viscosity increasing agent is in an amount from about 0.5% to about 2% w/w.

21. (Canceled)

22. (Previously Presented) The pharmaceutical composition according to claim 9, wherein the surfactant is a non-ionic surfactant.

23. (Canceled)

24. (Original) The pharmaceutical composition according to claim 8, wherein the topical formulation is selected from the group consisting of lotions, creams, gels, sticks, sprays, ointments and pastes.

25. (Previously Presented) A pharmaceutical composition for topical administration comprising the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base; 1.5% of prilocaine base; 4% of tetracaine base; 10% of methylpyrrolidone; 2% of dimethyl sulfoxide; 0.08% of topical hyaluronidase; 1.5% of guar gum; 1% of Tween[®] 20 (polyoxyethylenesorbitan monolaurate; CAS No: 9005-64-

5); 0.5% of Tween® 80 (polyoxyethylenesorbitan monooleate, CAS No: 9005-65-6), and the necessary amount of water to 100%.

26. (Currently Amended) A method of use of a composition comprising lidocaine, prilocaine and tetracaine, any of which being as such or as a pharmaceutically acceptable salt, the method being for eliciting an anesthetic effect and comprising:

providing a combination of lidocaine, prilocaine and tetracaine themselves or as pharmaceutically acceptable salts thereof; and,

administering the composition topically without occlusion.